LQDA Liquidia Corporation

Liquidia Announces Closing of Public Offering of Common Stock

Liquidia Announces Closing of Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced the closing of its previously announced underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00, for total gross proceeds of $75 million, before deducting underwriting discounts and commissions and expenses payable by Liquidia. All of the shares in the offering were sold by Liquidia. In addition, Liquidia has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less the underwriting discount and commissions.

Jefferies acted as the sole book-running manager for the offering. Needham & Company and Wedbush PacGrow acted as co-managers.

The shares of common stock described above were offered by Liquidia pursuant to its shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Liquidia with the Securities and Exchange Commission (the “SEC”) on August 23, 2019 and declared effective by the SEC on September 10, 2019. The proposed offering was made only by means of a written prospectus and prospectus supplement that form part of the registration statement. A preliminary prospectus supplement and accompanying prospectus and a final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available at the SEC’s website located at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at .

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact Information



Media:

Michael Parks

Corporate Communications

484.356.7105

Investors:

Jason Adair

Vice President, Corporate Development and Strategy

919.328.4400

EN
02/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Liquidia Corporation

 PRESS RELEASE

Liquidia Corporation to Report Full Year 2025 Financial Results on Mar...

Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026 MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that it will report its full year 2025 financial results on Thursday, March 5, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia’s website at . A rebroadcast of the ev...

 PRESS RELEASE

Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonar...

Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertensi...

 PRESS RELEASE

Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net...

Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in June 2025Generated more than $30 million of positive cash flow during the fourth quarter 2025 MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging ...

 PRESS RELEASE

Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare ...

Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California. Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at . The webcast will be archive...

 PRESS RELEASE

Liquidia Corporation to Present at Upcoming Healthcare Investment Conf...

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing updates on the company's business during fireside chats at the following two investor conferences in November: 2025 UBS Global Healthcare Conference on Monday, November 10 beginning at 4:15 p.m. ET in Palm Beach Gardens, F...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch